Losartan and Emotional Memory
The Effect of Losartan on Emotional Memory in Healthy Volunteers
1 other identifier
interventional
53
1 country
1
Brief Summary
This study explores the effects of single-dose losartan (50mg) versus identical placebo capsule on emotional memory and learning in healthy volunteers.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for not_applicable
Started Mar 2018
Shorter than P25 for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
March 1, 2018
CompletedPrimary Completion
Last participant's last visit for primary outcome
September 28, 2018
CompletedStudy Completion
Last participant's last visit for all outcomes
September 28, 2018
CompletedFirst Submitted
Initial submission to the registry
November 27, 2018
CompletedFirst Posted
Study publicly available on registry
December 4, 2018
CompletedDecember 6, 2018
November 1, 2018
7 months
November 27, 2018
December 4, 2018
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
aversive and appetitive learning
a learning task wil assess to what degree participants learn from win versus loss outcomes in different environments
1 hour after capsule intake
Study Arms (2)
losartan
EXPERIMENTAL50 mg single-dose oral losartan
placebo
PLACEBO COMPARATORmicrocellulose placebo in identical capsule
Interventions
Eligibility Criteria
You may qualify if:
- willing and able to provide informed consent
- male or Female, aged 18-50
- body mass index (BMI) of 18-30 kg/m2
- fluent English skills
- non- or light-smoker (\< 5 cigarettes a day)
You may not qualify if:
- Female participant who is pregnant or breast-feeding
- CNS-active medication during the last 6 weeks
- Current blood pressure or other heart medication (especially aliskiren or beta blockers)
- Intravascular fluid depletion
- Past or present DSM-IV axis-I diagnosis or suspected diagnosis (from SCID results at screening)
- Alcohol or substance abuse
- First-degree family member with a history of a severe psychiatric disease
- Impaired liver or kidney function
- Lifetime history of epilepsy or other neurological disease, systemic infection, or clinically significant hepatic, cardiac, obstructive respiratory, renal, cerebrovascular, metabolic, endocrine or pulmonary disease or disorder which, in the opinion of the investigator, may either put the participants at risk because of participation in the study, or may influence the result of the study, or the participant's ability to participate in the study.
- Insufficient English skills
- participated in another study involving CNS-active medication during the last 6 weeks
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Department of Psychiatry, University of Oxford
Oxford, OX37JX, United Kingdom
Related Publications (1)
Pulcu E, Shkreli L, Holst CG, Woud ML, Craske MG, Browning M, Reinecke A. The Effects of the Angiotensin II Receptor Antagonist Losartan on Appetitive Versus Aversive Learning: A Randomized Controlled Trial. Biol Psychiatry. 2019 Sep 1;86(5):397-404. doi: 10.1016/j.biopsych.2019.04.010. Epub 2019 Apr 17.
PMID: 31155138DERIVED
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- DOUBLE
- Who Masked
- PARTICIPANT, INVESTIGATOR
- Masking Details
- double-blind
- Purpose
- BASIC SCIENCE
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
November 27, 2018
First Posted
December 4, 2018
Study Start
March 1, 2018
Primary Completion
September 28, 2018
Study Completion
September 28, 2018
Last Updated
December 6, 2018
Record last verified: 2018-11